Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Charles River Laboratories Reaffirms Outlook For FY24 Revenue Growth Of 1.0%-4.0% And Adj EPS Of $10.90-$11.40, Est $11.02

Author: Benzinga Newsdesk | May 09, 2024 07:11am

 Despite modest adjustments to the quarterly gating in 2024, the Company's outlook for the year remains essentially unchanged and it is reaffirming revenue growth and non-GAAP earnings per share guidance, with the continued expectation that demand trends will improve modestly during the second half of the year.

Posted In: CRL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist